Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trulicity Takes Hit From Payer Mix, But Lilly Emerges From Q3 Ahead

COVID-19 Antibody Bamlanivimab Fails In Sicker Patients

Executive Summary

US pricing for Trulicity due to payer mix fluctuations dragged down solid volume growth. Lilly hopes revenue from COVID-19 therapies will help it hit annual guidance, but bamlanivimab failed to benefit hospitalized patients.

You may also be interested in...



Lilly Tries To Keep Investors Focused On The Pipeline, Not Performance

With disappointing revenues during Q1 due to the pandemic impact on sales and price pressure on Taltz, the pharma gave a long-term, pipeline-focused growth narrative. Alzheimer's filing plans pushed back.

Positive Atopic Dermatitis Data On Lilly's Newly-Approved Olumiant

It has gone under the radar that Eli Lilly and Incyte's Olumiant has recently become the first JAK inhibitor to be approved anywhere for atopic dermatitis and the companies have been touting promising long-term data on the therapy as it expands beyond rheumatoid arthritis.  

ViiV Looks Ahead With Third-Gen Integrase Inhibitor From Shionogi

License deal for preclinical S-365598 continues longstanding R&D relationship between ViiV and stakeholder Shionogi, which also developed dolutegravir and cabotegravir.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel